Development and Validation of the Computational Thinking Concepts and Skills Test

Calls for standardized and validated measures of computational thinking have been made repeatedly in recent years. Still, few such tests have been created and even fewer have undergone rig- orous psychometric evaluation and been made available to re- searchers. The purpose of this study is to report our work in de- veloping and validating a test of computational thinking concepts and skills and to compare different scoring methods for the test. This computational thinking exam is intended to be used in com- puting education research as a common measure of computational thinking so that the research community will be able to make more meaningful comparisons across samples and studies. The Computational Thinking Concepts and Skills Test (CTCAST) was administered to students in several courses, evaluated and revised, and then administered to another group of students. Part of the revision included changing half of the items to a multiple-select format. The test scores using the three scoring methods were com- pared to each other and to scores on a different test of core com- puter science knowledge. Results indicate the CTCAST and the test of core computer science knowledge measure similar, but not identical, aspects of students’ knowledge and skills, and that item- level statistics vary according to the scoring method that is used. Recommendations for using and scoring the test are presented

Development and Validation of the Computational Thinking Concepts and Skills Test

Calls for standardized and validated measures of computational thinking have been made repeatedly in recent years. Still, few such tests have been created and even fewer have undergone rig- orous psychometric evaluation and been made available to re- searchers. The purpose of this study is to report our work in de- veloping and validating a test of computational thinking concepts and skills and to compare different scoring methods for the test. This computational thinking exam is intended to be used in com- puting education research as a common measure of computational thinking so that the research community will be able to make more meaningful comparisons across samples and studies. The Computational Thinking Concepts and Skills Test (CTCAST) was administered to students in several courses, evaluated and revised, and then administered to another group of students. Part of the revision included changing half of the items to a multiple-select format. The test scores using the three scoring methods were com- pared to each other and to scores on a different test of core com- puter science knowledge. Results indicate the CTCAST and the test of core computer science knowledge measure similar, but not identical, aspects of students’ knowledge and skills, and that item- level statistics vary according to the scoring method that is used. Recommendations for using and scoring the test are presented

Development and Validation of the Computational Thinking Concepts and Skills Test

Calls for standardized and validated measures of computational thinking have been made repeatedly in recent years. Still, few such tests have been created and even fewer have undergone rig- orous psychometric evaluation and been made available to re- searchers. The purpose of this study is to report our work in de- veloping and validating a test of computational thinking concepts and skills and to compare different scoring methods for the test. This computational thinking exam is intended to be used in com- puting education research as a common measure of computational thinking so that the research community will be able to make more meaningful comparisons across samples and studies. The Computational Thinking Concepts and Skills Test (CTCAST) was administered to students in several courses, evaluated and revised, and then administered to another group of students. Part of the revision included changing half of the items to a multiple-select format. The test scores using the three scoring methods were com- pared to each other and to scores on a different test of core com- puter science knowledge. Results indicate the CTCAST and the test of core computer science knowledge measure similar, but not identical, aspects of students’ knowledge and skills, and that item- level statistics vary according to the scoring method that is used. Recommendations for using and scoring the test are presented

MicroMAPS CO Measurements over North America and Europe during Summer-Fall 2004

The MicroMAPS instrument is a nadir-viewing, gas filter-correlated radiometer which operating in the 4.67 micrometer fundamental band of carbon monoxide. Originally designed and built for a space mission, this CO remote sensor is being flown in support of satellite validation and science instrument demonstrations for potential UAV applications. The MicroMAPS instrument system, as flown on Proteus, was designed by a senior student design project in the Aerospace Engineering Department, Virginia Tech, in Blacksburg, VA. and then revised by Systems Engineers at NASA Langley. The final instrument system was integrated and tested at NASA LaRC, in partnership with Scaled Composites and Virginia Space Grant Consortium (VSGC). VSGC supervised the fabrication of the nacelle that houses the instrument system on the right rear tail boom of Proteus. Full system integration and flight testing was performed at Scaled Composites, in Mojave, in June 2004. Its successful performance enabled participation in four international science missions on Proteus: in 2004, INTEX -NA over eastern North America in July, ADRIEX over the Mediterranean region and EAQUATE over the United Kingdom region in September,and TWP-ICE over Darwin, Australia and the surrounding oceans in Jan-Feb 2006. These flights resulted in nearly 300 hours of data. In parallel with the engineering developments, theoretical radiative transfer models were developed specifically for the MicroMAPS instrument system at the University of Virginia, Mechanical Engineering Department by a combined undergraduate and graduate student team. With technical support from Resonance Ltd. in June 2005, the MicroMAPS instrument was calibrated for the conditions under which the Summer-Fall 2004 flights occurred. The analyses of the calibration data, combined with the theoretical radiative transfer models, provide the first data reduction for the science flights reported here. These early results and comparisons with profile data from the NASA DC-8, the coincident AIRS CO retrievals, and selected CO measurements from the MOZAIC program will be presented

Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population

Abstract Background Previous population-based studies have described first primary breast cancer tumor characteristics and their association with contralateral breast cancer (CBC) risk. However, information on influential covariates such as treatment, family history of breast cancer, and BRCA1/2 mutation carrier status was not available. In a large, population-based, case-control study, we evaluated whether tumor characteristics of the first primary breast cancer are associated with risk of developing second primary asynchronous CBC, overall and in subgroups of interest, including among BRCA1/2 mutation non-carriers, women who are not treated with tamoxifen, and women without a breast cancer family history. Methods The Women’s Environmental Cancer and Radiation Epidemiology Study is a population-based case-control study of 1521 CBC cases and 2212 individually-matched controls with unilateral breast cancer. Detailed information about breast cancer risk factors, treatment for and characteristics of first tumors, including estrogen receptor (ER) and progesterone receptor (PR) status, was obtained by telephone interview and medical record abstraction. Multivariable risk ratios (RRs) and 95% confidence intervals (CIs) were estimated in conditional logistic regression models, adjusting for demographics, treatment, and personal medical and family history. A subset of women was screened for BRCA1/2 mutations. Results Lobular histology of the first tumor was associated with a 30% increase in CBC risk (95% CI 1.0–1.6). Compared to women with ER+/PR+ first tumors, those with ER-/PR- tumors had increased risk of CBC (RR = 1.4, 95% CI 1.1–1.7). Notably, women with ER-/PR- first tumors were more likely to develop CBC with the ER-/PR- phenotype (RR = 5.4, 95% CI 3.0–9.5), and risk remained elevated in multiple subgroups: BRCA1/2 mutation non-carriers, women younger than 45 years of age, women without a breast cancer family history, and women who were not treated with tamoxifen. Conclusions Having a hormone receptor negative first primary breast cancer is associated with increased risk of CBC. Women with ER-/PR- primary tumors were more likely to develop ER-/PR- CBC, even after excluding BRCA1/2 mutation carriers. Hormone receptor status, which is routinely evaluated in breast tumors, may be used clinically to determine treatment protocols and identify patients who may benefit from increased surveillance for CBC

Indoor Social Networks in a South African Township: Potential Contribution of Location to Tuberculosis Transmission

CITATION: Wood, R. et al. 2012. Indoor social networks in a South African township : potential contribution of location to tuberculosis transmission. PLoS ONE, 7(6): e39246, doi:10.1371/journal.pone.0039246.The original publication is available at http://journals.plos.org/plosoneBackground We hypothesized that in South Africa, with a generalized tuberculosis (TB) epidemic, TB infection is predominantly acquired indoors and transmission potential is determined by the number and duration of social contacts made in locations that are conducive to TB transmission. We therefore quantified time spent and contacts met in indoor locations and public transport by residents of a South African township with a very high TB burden. Methods A diary-based community social mixing survey was performed in 2010. Randomly selected participants (n = 571) prospectively recorded numbers of contacts and time spent in specified locations over 24-hour periods. To better characterize age-related social networks, participants were stratified into ten 5-year age strata and locations were classified into 11 types. Results Five location types (own-household, other-households, transport, crèche/school, and work) contributed 97.2% of total indoor time and 80.4% of total indoor contacts. Median time spent indoors was 19.1 hours/day (IQR:14.3–22.7), which was consistent across age strata. Median daily contacts increased from 16 (IQR:9–40) in 0–4 year-olds to 40 (IQR:18–60) in 15–19 year-olds and declined to 18 (IQR:10–41) in ≥45 year-olds. Mean daily own-household contacts was 8.8 (95%CI:8.2–9.4), which decreased with increasing age. Mean crèche/school contacts increased from 6.2/day (95%CI:2.7–9.7) in 0–4 year-olds to 28.1/day (95%CI:8.1–48.1) in 15–19 year-olds. Mean transport contacts increased from 4.9/day (95%CI:1.6–8.2) in 0–4 year-olds to 25.5/day (95%CI:12.1–38.9) in 25–29 year-olds. Conclusions A limited number of location types contributed the majority of indoor social contacts in this community. Increasing numbers of social contacts occurred throughout childhood, adolescence, and young adulthood, predominantly in school and public transport. This rapid increase in non-home socialization parallels the increasing TB infection rates during childhood and young adulthood reported in this community. Further studies of the environmental conditions in schools and public transport, as potentially important locations for ongoing TB infection, are indicated.http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0039246Publisher's versio

A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome

<p>Abstract</p> <p>Background</p> <p>The tissue factor (TF)-dependent extrinsic pathway has been suggested to be a central mechanism by which the coagulation cascade is locally activated in the lungs of patients with acute lung injury and acute respiratory distress syndrome (ALI/ARDS) and thus represents an attractive target for therapeutic intervention. This study was designed to determine the pharmacokinetic and safety profiles of ALT-836, an anti-TF antibody, in patients with ALI/ARDS.</p> <p>Methods</p> <p>This was a prospective, randomized, placebo-controlled, dose-escalation Phase I clinical trial in adult patients who had suspected or proven infection, were receiving mechanical ventilation and had ALI/ARDS (PaO₂/FiO₂≤ 300 mm). Eighteen patients (6 per cohort) were randomized in a 5:1 ratio to receive ALT-836 or placebo, and were treated within 48 hours after meeting screening criteria. Cohorts of patients were administered a single intravenously dose of 0.06, 0.08 or 0.1 mg/kg ALT-836 or placebo. Blood samples were taken for pharmacokinetic and immunogenicity measurements. Safety was assessed by adverse events, vital signs, ECGs, laboratory, coagulation and pulmonary function parameters.</p> <p>Results</p> <p>Pharmacokinetic analysis showed a dose dependent exposure to ALT-836 across the infusion range of 0.06 to 0.1 mg/kg. No anti-ALT-836 antibody response was observed in the study population during the trial. No major bleeding episodes were reported in the ALT-836 treated patients. The most frequent adverse events were anemia, observed in both placebo and ALT-836 treated patients, and ALT-836 dose dependent, self-resolved hematuria, which suggested 0.08 mg/kg as an acceptable dose level of ALT-836 in this patient population.</p> <p>Conclusions</p> <p>Overall, this study showed that ALT-836 could be safely administered to patients with sepsis-induced ALI/ARDS.</p> <p>Trial registration</p> <p>ClinicalTrials.gov: <a href="http://www.clinicaltrials.gov/ct2/show/NCT01438853">NCT01438853</a></p

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND). a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Background: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or those with lesion activity on imaging. We sought to assess whether natalizumab slows disease progression in secondary progressive multiple sclerosis, independent of relapses. Methods: ASCEND was a phase 3, randomised, double-blind, placebo-controlled trial (part 1) with an optional 2 year open-label extension (part 2). Enrolled patients aged 18–58 years were natalizumab-naive and had secondary progressive multiple sclerosis for 2 years or more, disability progression unrelated to relapses in the previous year, and Expanded Disability Status Scale (EDSS) scores of 3·0–6·5. In part 1, patients from 163 sites in 17 countries were randomly assigned (1:1) to receive 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. Patients were stratified by site and by EDSS score (3·0–5·5 vs 6·0–6·5). Patients completing part 1 could enrol in part 2, in which all patients received natalizumab every 4 weeks until the end of the study. Throughout both parts, patients and staff were masked to the treatment received in part 1. The primary outcome in part 1 was the proportion of patients with sustained disability progression, assessed by one or more of three measures: the EDSS, Timed 25-Foot Walk (T25FW), and 9-Hole Peg Test (9HPT). The primary outcome in part 2 was the incidence of adverse events and serious adverse events. Efficacy and safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01416181. Findings: Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned (n=440 to the natalizumab group, n=449 to the placebo group). In part 1, 195 (44%) of 439 natalizumab-treated patients and 214 (48%) of 448 placebo-treated patients had confirmed disability progression (odds ratio [OR] 0·86; 95% CI 0·66–1·13; p=0·287). No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74–1·53; nominal p=0·753) or the T25FW (0·98, 0·74–1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT progression (OR 0·56, 95% CI 0·40–0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108–221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab. Two deaths occurred in part 1, neither of which was considered related to study treatment. No progressive multifocal leukoencephalopathy occurred. Interpretation: Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components. Funding: Biogen

Medical conditions in autism spectrum disorders

Autism spectrum disorder (ASD) is a behaviourally defined syndrome where the etiology and pathophysiology is only partially understood. In a small proportion of children with the condition, a specific medical disorder is identified, but the causal significance in many instances is unclear. Currently, the medical conditions that are best established as probable causes of ASD include Fragile X syndrome, Tuberous Sclerosis and abnormalities of chromosome 15 involving the 15q11-13 region. Various other single gene mutations, genetic syndromes, chromosomal abnormalities and rare de novo copy number variants have been reported as being possibly implicated in etiology, as have several ante and post natal exposures and complications. However, in most instances the evidence base for an association with ASD is very limited and largely derives from case reports or findings from small, highly selected and uncontrolled case series. Not only therefore, is there uncertainty over whether the condition is associated, but the potential basis for the association is very poorly understood. In some cases the medical condition may be a consequence of autism or simply represent an associated feature deriving from an underlying shared etiology. Nevertheless, it is clear that in a growing proportion of individuals potentially causal medical conditions are being identified and clarification of their role in etio-pathogenesis is necessary. Indeed, investigations into the causal mechanisms underlying the association between conditions such as tuberous sclerosis, Fragile X and chromosome 15 abnormalities are beginning to cast light on the molecular and neurobiological pathways involved in the pathophysiology of ASD. It is evident therefore, that much can be learnt from the study of probably causal medical disorders as they represent simpler and more tractable model systems in which to investigate causal mechanisms. Recent advances in genetics, molecular and systems biology and neuroscience now mean that there are unparalleled opportunities to test causal hypotheses and gain fundamental insights into the nature of autism and its development